1. Home
  2. PDO vs BEAM Comparison

PDO vs BEAM Comparison

Compare PDO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDO
  • BEAM
  • Stock Information
  • Founded
  • PDO 2020
  • BEAM 2017
  • Country
  • PDO United States
  • BEAM United States
  • Employees
  • PDO N/A
  • BEAM N/A
  • Industry
  • PDO Trusts Except Educational Religious and Charitable
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PDO Finance
  • BEAM Health Care
  • Exchange
  • PDO Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • PDO 1.6B
  • BEAM 1.8B
  • IPO Year
  • PDO N/A
  • BEAM 2020
  • Fundamental
  • Price
  • PDO $13.29
  • BEAM $19.87
  • Analyst Decision
  • PDO
  • BEAM Strong Buy
  • Analyst Count
  • PDO 0
  • BEAM 11
  • Target Price
  • PDO N/A
  • BEAM $50.50
  • AVG Volume (30 Days)
  • PDO 520.0K
  • BEAM 3.0M
  • Earning Date
  • PDO 01-01-0001
  • BEAM 05-06-2025
  • Dividend Yield
  • PDO 11.80%
  • BEAM N/A
  • EPS Growth
  • PDO N/A
  • BEAM N/A
  • EPS
  • PDO N/A
  • BEAM N/A
  • Revenue
  • PDO N/A
  • BEAM $63,518,000.00
  • Revenue This Year
  • PDO N/A
  • BEAM N/A
  • Revenue Next Year
  • PDO N/A
  • BEAM $6.32
  • P/E Ratio
  • PDO N/A
  • BEAM N/A
  • Revenue Growth
  • PDO N/A
  • BEAM N/A
  • 52 Week Low
  • PDO $10.65
  • BEAM $13.53
  • 52 Week High
  • PDO $13.31
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • PDO 49.79
  • BEAM 51.79
  • Support Level
  • PDO $12.93
  • BEAM $16.04
  • Resistance Level
  • PDO $13.17
  • BEAM $19.48
  • Average True Range (ATR)
  • PDO 0.44
  • BEAM 1.68
  • MACD
  • PDO 0.04
  • BEAM 0.69
  • Stochastic Oscillator
  • PDO 73.63
  • BEAM 87.11

About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest

PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: